Regarding the development of a putative therapy based on B-cell lymphoma exosomes, Aung et al. [163] demonstrated that these exosomes, carrying CD20 and lysosome-related organelle-associated ATP Binding Cassette Subfamily A Member 3 (ABCA3), bound to the therapeutic anti-CD20 antibody and the consumed complement, hereby impaired antibody-dependent cell-mediated cytotoxicity (ADCC) and protected cancer cells from antibody attack. This evidence concerns the gene ABCA3 and B-cell non-Hodgkin lymphoma.